CRDL
Cardiol Therapeutics, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CA
$1.88
+0.81%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.86
From 52W high−17.94%
Volume967613.00
Market cap$227.84M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$1.86
From 52W high
−17.94%
Volume
967613.00
Market cap
$227.84M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−7.9x
P/E (TTM)
—
RSI (14)
50.0
MomentumView details →
1D Return
+0.81%
YTD Return
+98.15%
SummaryUpdated Jun 1, 2026
Cardiol Therapeutics Inc. (NASDAQ:CRDL) is a clinical-stage Canadian biopharmaceutical company founded in 2017 and headquartered in Oakville, Ontario. The company went public in January 2019 and focuses on developing innovative therapies to treat cardiovascular diseases through anti-fibrotic and anti-inflammatory approaches. As a clinical-stage company, Cardiol has no commercial products yet and is currently conducting Phase II/III trials for its lead drug candidate, CardiolRx, targeting heart-related conditions including COVID-19 cardiovascular complications and acute myocarditis.
Similar companies
Latest newsMore news →
Cardiol Therapeutics announced the exercise of warrants for over USD 7 million in proceeds, strengthening its balance sheet ahead of Phase III MAVERIC trial data in recurrent pericarditis.4d agoCardiol Therapeutics filed a preliminary short form base shelf prospectus for up to US$150 million with Canadian securities regulators and a corresponding Form F-10 registration statement with the US SEC.10d ago